Table 1.
Phase 1 (n=100) (%) | Phase 2 (n=102) (%) | OR | 95% CI | p Value | Phase 3 (n=105) (%) | OR | 95% CI | p Value | |
---|---|---|---|---|---|---|---|---|---|
Female sex (%) | 60 | 43 | 0.50 | 0.29 to 0.88 | <0.02 | 38 | 0.41 | 0.23 to 0.72 | <0.01 |
PDR (%) | 22 | 43 | 2.67 | 1.44 to 4.96 | <0.01 | 50 | 3.55 | 1.92 to 6.55 | <0.01 |
ADR (%) | 14 | 33 | 3.03 | 1.50 to 6.11 | <0.01 | 37 | 3.61 | 1.80 to 7.23 | <0.01 |
Mean WT (min) | 6.8 | 7.2 | 0.73 | 10.9 | <0.01 | ||||
WT ≥6 min | 53 | 71 | 2.17 | 1.21 to 3.89 | <0.01 | 87 | 5.93 | 2.94–11.98 | <0.01 |
WT ≥8 min | 34 | 44 | 1.53 | 0.86 to 2.70 | 0.15 | 74 | 5.52 | 3.00 to 10.16 | <0.01 |
p Values are comparison with the preintervention phase 1.
ADR, adenoma detection rate; PDR, polyp detection rate; WT, withdrawal time.